UCB PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
UCB SA (0NZT)
73.45
-0.18(-0.24%)
- Volume:106,713
- Bid/Ask:0.00/0.00
- Day's Range:73.45 - 73.45
0NZT Overview
- Prev. Close
- 73.63
- Day's Range
- 73.45-73.45
- Revenue
- -
- Open
- 74.25
- 52 wk Range
- 72.44-116
- EPS
- 4.68
- Volume
- 106,713
- Market Cap
- 13.89B
- Dividend (Yield)
- 0.91(1.24%)
- Average Volume (3m)
- 193,200
- P/E Ratio
- 16.14
- Beta
- 0.394
- 1-Year Change
- -24.9%
- Shares Outstanding
- 189,958,817
- Next Earnings Date
- 01 Nov 2022
What is your sentiment on UCB?
or
Market is currently closed. Voting is open during market hours.
UCB SA News
- UCB Earnings miss, Revenue Inline In Q2
- ByInvesting.com-
Investing.com - UCB reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. UCB announced earnings per share...
- UCB Earnings, Revenue miss in Q4
- ByInvesting.com-
Investing.com - UCB reported on Thursday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. UCB announced earnings per share of...
UCB SA Company Profile
UCB SA Company Profile
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Sell | Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.25 | 7.40 | 7.25 | 0.00 | 0.00% | 284.82K | London | |||
| 93.90 | 94.00 | 92.00 | +1.30 | +1.40% | 304.64K | London | |||
| 317.50 | 325.00 | 315.00 | +0.50 | +0.16% | 195.99K | London | |||
| 85.01 | 85.89 | 84.22 | +0.25 | +0.29% | 15.14M | London | |||
| 121.58 | 122.02 | 120.48 | +0.36 | +0.30% | 24.58M | London | |||
| 175.60 | 176.15 | 171.95 | +2.75 | +1.59% | 4.28M | London | |||
| 219.00 | 224.60 | 218.30 | -3.20 | -1.44% | 4.61M | London | |||
| 359.60 | 368.40 | 357.60 | -14.40 | -3.85% | 1.75M | London | |||
| 25.96 | 26.30 | 25.40 | +0.42 | +1.64% | 2.38M | London | |||
| 118.10 | 119.50 | 117.34 | -0.60 | -0.51% | 11.66M | London | |||
| 606.20 | 610.00 | 599.60 | +6.80 | +1.13% | 4.62M | London | |||
| 157.90 | 159.70 | 157.20 | -0.10 | -0.06% | 9.95M | London | |||
| 412.00 | 413.50 | 410.50 | +2.50 | +0.61% | 415.44K | London | |||
| 430.55 | 435.90 | 427.75 | +3.00 | +0.70% | 28.57M | London | |||
| 136.15 | 137.65 | 134.45 | -0.10 | -0.07% | 2.80M | London |